TL;DR
This study establishes a novel reporter system to dissect the regulation of HOXA9, a key driver in aggressive leukemias. Using this system with CRISPR screens, they identified USF2 as a critical transcription factor for HOXA9 expression and MLLr leukemia cell proliferation, opening new avenues for therapeutic development.
What Problem Does This Paper Address?
HOXA9 is a transcription factor whose aberrant overexpression is a hallmark of aggressive acute leukemias, particularly those with KMT2A (MLL) gene rearrangements. This overexpression is linked to poor prognosis and plays a crucial role in leukemia development and maintenance. However, the precise molecular mechanisms governing HOXA9 regulation in these leukemias remain poorly understood, limiting the development of targeted therapies. The authors aimed to overcome this by creating a system that allows for real-time monitoring of HOXA9 expression and using it to systematically identify the upstream regulators controlling its activity.
Methods
The core of this study is the development of a HOXA9-mCherry knock-in reporter cell line. This was achieved using a "CHASE knock-in" strategy, where a P2A-mCherry cassette was inserted upstream of the HOXA9 stop codon in SEM (B-ALL MLLr) and OCI-AML2 (AML MLLr) cell lines. This reporter system allows for the endogenous HOXA9 expression to be directly visualized and quantified via mCherry fluorescence.
To identify regulatory factors, the researchers employed CRISPR/Cas9 loss-of-function screens. They utilized a pooled sgRNA library targeting 1639 human transcription factors. Cells were sorted based on mCherry expression (high vs. low) to identify sgRNAs that significantly altered HOXA9 levels. To account for potential survival biases, a secondary screen was performed in cells where HOXA9 expression was ectopically rescued by co-expression with its partner MEIS1.
Further validation involved siRNA-mediated knockdown and auxin-inducible degron (AID) systems for acute protein depletion. Cut and Run assays were used to assess the direct binding of identified regulators to the HOXA9 promoter. Standard techniques like qPCR, Western blotting, and flow cytometry were used for gene expression analysis and cell population characterization.
Datasets
The study generated new data through their CRISPR screens and reporter cell line experiments. They also utilized publicly available datasets for HOXA9 expression profiling in leukemia (Figures 1E and S5D, GSE120781; Figure 1-supplement 1A-C, GSE13159) and for CTCF binding sites (ENCODE). Specific datasets related to other figures are cited in the "Data availability" section. No new benchmarks were introduced; rather, existing methods like MAGeCK and DESeq2 were used for data analysis.
Key Insights and Ideas
- A robust reporter system is crucial: The development of the HOXA9-mCherry knock-in reporter cell line was a critical enabler for this study, providing a direct and quantitative readout of endogenous HOXA9 activity.
- USF2 emerges as a key regulator: The CRISPR screens unexpectedly highlighted USF2 as a significant positive regulator of HOXA9. This was a novel finding, as previous research had focused more on epigenetic modifiers.
- USF2's role is specific to MLLr leukemia: While USF2 depletion impacted HOXA9 in MLLr cells, it did not have the same effect in non-MLLr leukemia cell lines, suggesting a context-dependent regulatory mechanism.
- CTCF's role is cell-type specific: Contrary to some previous findings, CTCF was found to be dispensable for maintaining HOXA9 expression in the SEM MLLr B-ALL cells, highlighting the complexity and context-dependency of chromatin regulation.
Key Results
- The HOXA9-mCherry reporter cell lines faithfully recapitulated endogenous HOXA9 transcription and responded to known regulators like DOT1L and ENL.
- CRISPR/Cas9 screens identified known regulators (HOXA9, DOT1L, KMT2A) and a novel regulator, USF2, as top hits controlling HOXA9 expression.
- Depletion of USF2 significantly reduced HOXA9 expression and impaired MLLr leukemia cell proliferation. This effect could be rescued by ectopic expression of HOXA9.
- USF2 was found to directly bind to the HOXA9 promoter region.
- USF1 and USF2 showed synergistic effects in regulating HOXA9 expression and leukemia cell survival in MLLr leukemia models.
- USF2 was identified as an essential gene for MLLr B-ALL cell proliferation.
Limitations and Future Work
- Cell-type specificity: The study highlights that the role of certain regulators, like CTCF, can be cell-type specific. While USF2's role in MLLr leukemia is established, its broader role in other HOXA9-driven cancers warrants further investigation.
- USF1/USF2 redundancy: The authors note that USF1 and USF2 can form homo- and heterodimers and exhibit some redundancy. While they showed synergistic effects in MLLr cells, the precise mechanisms of this synergy and the roles of individual USF proteins in other contexts require further exploration.
- HOXA9-independent functions: The study focuses on USF2's role in HOXA9 regulation. However, USF1/USF2 may have other HOXA9-independent functions in leukemia progression that need further investigation.
- Clinical relevance: While USF2 expression was found to be correlated with HOXA9 in MLLr patients, further studies are needed to fully elucidate the clinical implications of the USF2/HOXA9 axis.
The authors suggest that their HOXA9 reporter system is a valuable tool for future drug screening and identifying concordant epigenetic modifiers and transcription factors involved in HOXA9 activation and maintenance, paving the way for developing clinically relevant therapies.
Summary updated